Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 4,692 | 6,208 | 8,209 | 6,402 | 5,722 | 5,485 | 5,519 | 5,724 |
| Operating profit | €m | -105 | 74 | ||||||
| Net profit | €m | 189 | 807 | 1,251 | 314 | 241 | -821 | -433 | 81 |
| EPS reported | € | -16.53 | -8.83 | ||||||
| Operating cashflow per share | € | 11.08 | 14.86 | ||||||
| Capex per share | € | 11.14 | 8.52 | ||||||
| FCF per share | € | -0.06 | 6.34 | ||||||
| Free cash flow | €m | -3 | 316 | ||||||
| Net debt | €m | 609 | 386 | ||||||
| Book value equity | €m | 3,599 | 4,021 | ||||||
| Book value per share | € | 72.45 | 80.69 | ||||||
| Number of shares | m | 49.68 | 49.83 | ||||||
| DPS (TTM paid) | € | 2.50 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.96 | 1.10 | ||||||
| P/S LTM | x | 0.63 | 0.80 | ||||||
| P/FCF LTM | x | -1,230.42 | 13.98 | ||||||
| EV/EBITDA LTM | x | 11.87 | 8.77 | ||||||
| EV/Sales LTM | x | 0.86 | 0.87 | ||||||
| Earnings Yield LTM | % | -23.83% | -9.77% | ||||||
| FCF Yield | % | -0.08% | 7.15% | ||||||
| Quality | |||||||||
| ROE | % | -22.81% | -11.14% | ||||||
| ROIC | % | -1.37% | 0.98% | ||||||
| Operating margin | % | -1.92% | 1.34% | ||||||
| Gross margin | % | 11.98% | 14.05% | ||||||
| FCF/Sales | % | -0.05% | 5.72% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -4.14% | -2.42% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | -51.16% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 3.61% | 0.00% | ||||||
| Dividend Growth | % | - | -100.00% | ||||||
| Payout Ratio | % | -15.12% | -5.10% | ||||||
| FCF/Debt | x | -0.00 | 0.14 | ||||||
| Net Debt/EBITDA | x | 3.19 | 2.61 | ||||||
| EBIT/Net interest | x | -0.62 | 0.40 | ||||||
| Net debt/market cap | % | 17.67% | 8.73% | ||||||
| Net debt/Equity | x | 0.17 | 0.10 | ||||||
| Gross debt/equity | x | 0.66 | 0.57 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Wacker Chemie AG is a global enterprise delivering a diverse portfolio of chemical products through its worldwide operations. The company's business is structured across four principal divisions: Wacker Silicones, Wacker Polymers, Wacker Biosolutions, and Wacker Polysilicon. The Wacker Silicones segment produces an extensive array of silicone-based items, including silanes, siloxanes, fluids, emulsions, elastomers, resins, and pyrogenic silicas, which are essential for industries such as construction, electronics, automotive, healthcare, and renewable energy. Meanwhile, Wacker Polymers specializes in the provision of binders and polymeric additives, notably dispersible polymer powders and vinyl acetate-ethylene dispersions, crucial for applications in construction, paper manufacturing, adhesives, paints, coatings, and fundamental chemical processes. Wacker Biosolutions focuses on bespoke biotechnological solutions and a specialized catalog of fine chemicals. Its offerings, encompassing pharmaceutical proteins, vaccines, cyclodextrins, cysteine, polyvinyl acetate solid resins, and acetylacetone, serve as key components for pharmaceutical active ingredients, food additives, and agricultural chemicals. Finally, the Wacker Polysilicon unit is dedicated to manufacturing hyperpure polysilicon, an indispensable material for both the semiconductor and solar energy sectors. Tracing its origins back to 1914, Wacker Chemie AG maintains its headquarters in Munich, Germany, and functions as a subsidiary of Dr. Alexander Wacker Familiengesellschaft mbH.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Wacker Chemie AG is a global enterprise delivering a diverse portfolio of chemical products through its worldwide operations. The company's business is structured across four principal divisions: Wacker Silicones, Wacker Polymers, Wacker Biosolutions, and Wacker Polysilicon. The Wacker Silicones segment produces an extensive array of silicone-based items, including silanes, siloxanes, fluids, emulsions, elastomers, resins, and pyrogenic silicas, which are essential for industries such as construction, electronics, automotive, healthcare, and renewable energy. Meanwhile, Wacker Polymers specializes in the provision of binders and polymeric additives, notably dispersible polymer powders and vinyl acetate-ethylene dispersions, crucial for applications in construction, paper manufacturing, adhesives, paints, coatings, and fundamental chemical processes. Wacker Biosolutions focuses on bespoke biotechnological solutions and a specialized catalog of fine chemicals. Its offerings, encompassing pharmaceutical proteins, vaccines, cyclodextrins, cysteine, polyvinyl acetate solid resins, and acetylacetone, serve as key components for pharmaceutical active ingredients, food additives, and agricultural chemicals. Finally, the Wacker Polysilicon unit is dedicated to manufacturing hyperpure polysilicon, an indispensable material for both the semiconductor and solar energy sectors. Tracing its origins back to 1914, Wacker Chemie AG maintains its headquarters in Munich, Germany, and functions as a subsidiary of Dr. Alexander Wacker Familiengesellschaft mbH.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free